Top Boehringer In­gel­heim drug gets FDA ap­proval in rare skin dis­ease

For many pa­tients with gen­er­al­ized pus­tu­lar pso­ri­a­sis (GPP), the jour­ney to di­ag­no­sis could take years, as doc­tors can mis­take the in­cred­i­bly rare skin con­di­tion for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER